FDA approves new indication for Takeda’s HyQvia

After first approving the drug in 2014 for the treatment of primary immunodeficiency (PI) in adults, the US Food and Drug Administration (FDA) has now approved a new indication for HyQvia [immune globulin Infusion 10% (Human) with recombinant human hyaluronidase].

Marketed by Japan’s largest drugmaker Takeda (TYO: 4502), HyQvia is now authorized for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.

HyQvia is co-formulated with Halozyme's ENHANZE drug delivery technology